Lupin Pharmaceuticals, Inc. (LPI) has received final approval for the Company's ANDA for Levetiracetam Tablets 250mg, 500mg, 750mg and 1000mg from the USFDA. Commercial shipments of the product have commenced. Lupin's Levetiracetam tablets are the AB-rated generic equivalent of UCB Pharmaceuticals' Keppra(R) tablets, indicated as adjunctive therapy in the treatment of certain types of seizures associated with epilepsy.
No comments:
Post a Comment